Wells Fargo analyst Derek Archila raised the firm’s price target on Incyte (INCY) to $59 from $58 and keeps an Equal Weight rating on the shares. The firm acknowledges the “beat and raise” though, estimates move up mere 1% for Jakafi while Opzelura missed by a decent margin in Q1. Wells doesn’t view it as a great quarter, and without meaningful clinical catalysts in 2025, the firm is sticking to the sidelines.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte’s Growth Prospects Hindered by Jakafi’s Exclusivity Loss and Strategic Limitations
- Incyte price target raised to $89 from $87 at BofA
- Incyte Reports Strong Q1 2025 Financial Growth
- Incyte’s Q1 2025 Earnings: Strong Growth and Optimism
- Incyte’s Promising Growth Potential and Strategic Positioning Amidst Market Challenges